Envoy Medical COCHW
NASDAQ COCHW
$0.03 +0.00 (+0.00%)
At close: Nov 6, 2026 · 4:00 PM EST

Envoy Medical (COCHW) Change in Accrued Expenses (2021 - 2026)

Updated

Envoy Medical's Change in Accured Expenses came in at -$911,000 for Q2 2026, compared with $113,000 a year earlier.

Analysis

Envoy Medical (COCHW) Change in Accrued Expenses (2021 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Envoy Medical reported Change in Accured Expenses of $280,000, down 80.1% year-over-year; for FY2025, it was $839,000.

  • Change in Accured Expenses carries a five-year compound annual growth rate of 312.7% (FY2020 to FY2025).
  • Going back by year, Change in Accured Expenses was -$241,000 in FY2024, -$94,000 in FY2023, $133,000 in FY2022 (-93.5%) and $2.06 million in FY2021.
  • The Q2 2026 figure represents the lowest quarterly Change in Accured Expenses since Q2 2024.
  • Business Quant data shows COCHW's Change in Accured Expenses at $664,000 (Q1 2026), $623,000 (Q4 2025) and -$96,000 (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -911,000.00
Mar 31, 2026 664,000.00
Dec 31, 2025 623,000.00
Sep 30, 2025 -96,000.00
Jun 30, 2025 113,000.00
Mar 31, 2025 199,000.00
Dec 31, 2024 -205,000.00
Sep 30, 2024 1.30 Mn
Jun 30, 2024 -982,000.00
Mar 31, 2024 -357,000.00
Dec 31, 2023 -788,000.00
Sep 30, 2023 555,000.00
Jun 30, 2023 319,000.00
Mar 31, 2023 -180,000.00
Dec 31, 2022 237,000.00
Sep 30, 2022 -212,315.00
Jun 30, 2022 -471,724.00
Mar 31, 2022 580,039.00
Dec 31, 2021 86,470.00
Sep 30, 2021 1.54 Mn
API Access

Envoy Medical Change in Accrued Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=COCHW&period=max&api_key=YOUR_API_KEY